Table 1 Characteristics of COVID-19 patients receiving outpatient mAb treatment, stratified by hospitalization status
Characteristics, n (%) | No treatment failure n = 7148 (96.5%) | Treatment failure n = 258 (3.5%) | p-value |
|---|---|---|---|
Age in years | < 0.001 | ||
18–44 | 2055 (28.7) | 54 (21.0) | |
45–64 | 2767 (38.7) | 84 (32.3) | |
≥ 65 | 2326 (32.5) | 120 (46.7) | |
Sex | < 0.001 | ||
Male | 3172 (44.4) | 142 (55.3) | |
Female | 3976 (55.6) | 116 (44.7) | |
Race/ethnicity | 0.01 | ||
Non-Hispanic white | 5596 (81.3) | 194 (75.5) | |
Non-Hispanic black | 178 (2.6) | 14 (5.4) | |
Hispanic | 760 (11.0) | 37 (14.4) | |
Other | 351 (5.1) | 12 (4.7) | |
Insurance status | < 0.001 | ||
Private/commercial | 3931 (55.0) | 94 (36.4) | |
Medicare | 2292 (32.1) | 124 (48.1) | |
Medicaid | 511 (7.1) | 32 (12.4) | |
None/uninsured | 255 (3.6) | 3 (1.2) | |
Other/unknown | 159 (2.2) | 5 (1.9) | |
Obesity* | 1896 (27.1) | 119 (46.1) | < 0.001 |
Number of comorbidities | < 0.001 | ||
0 | 2825 (40.4) | 39 (15.1) | |
1 | 2042 (29.2) | 56 (21.7) | |
≥ 2 | 2129 (30.4) | 163 (63.2) | |
Cardiovascular disease | 1166 (16.7) | 112 (43.4) | < 0.001 |
Hypertension | 2743 (39.2) | 169 (65.5) | < 0.001 |
Pulmonary disease | 2022 (28.9) | 99 (38.5) | 0.001 |
Renal disease | 618 (8.8) | 77 (29.8) | < 0.001 |
Diabetes | 1136 (15.9) | 89 (34.5) | < 0.001 |
Immunocompromised | < 0.001 | ||
None | 5543 (77.5) | 163 (63.2) | |
Mild | 793 (11.1) | 38 (14.7) | |
Moderate/severe | 812 (11.4) | 57 (22.1) | |
SARS-CoV-2 vaccine doses | < 0.001 | ||
2+ | 2767 (38.7) | 61 (23.6) | |
1 | 503 (7.0) | 16 (6.2) | |
0 | 3878 (54.3) | 181 (70.2) | |
Pandemic phase | < 0.001 | ||
Pre-Alpha | 372 (5.2) | 25 (9.7) | |
Alpha | 422 (5.9) | 30 (11.6) | |
Delta | 6354 (88.9) | 203 (78.7) | |
Days to mAb treatment | 0.33 | ||
1 or less | 1604 (22.4) | 70 (27.1) | |
2 | 1396 (19.5) | 50 (19.4) | |
3 | 1319 (18.5) | 48 (18.6) | |
4 | 1041 (14.6) | 36 (14.0) | |
5 | 807 (11.3) | 31 (12.0) | |
6 | 456 (6.4) | 11 (4.3) | |
7–10 | 525 (7.3) | 12 (4.7) | |
mAb type | 0.008 | ||
Bamlanivimab | 400 (5.6) | 24 (9.3) | |
Bamlanivimab + etesevimab | 1003 (14.1) | 30 (11.6) | |
Bamlanivimab + imdevimab | 5190 (72.6) | 194 (75.2) | |
Sotrovimab | 541 (7.6) | 10 (3.9) | |